Roivant's $31 Million Proof Point — and the Trial That Read Out Before the FDA Did
Five weeks of LISRAYA revenue, an unexpected RA p-value, a quiet Sjögren's retreat, and a launch whose inventory math nobody will pin down
ROIV · Earnings Call · 2026-11-09
The first real revenue line, wrapped in fog
Roivant spent a decade as a company valued almost entirely on optionality. This quarter it became, for the first time, a company with a product on the market — and the market got exactly five weeks of data to argue about. LISRAYA (brepocitinib) was approved in late August for dermatomyositis and booked $31 million of net revenue in that stub period, against a total revenue base that in the last filed quarter was $1 million. That comparison is the whole investment case in one line. Management was unusually disciplined about not helping. Matt Gline confirmed “there were hundreds of patients on paid drug at the end of the quarter” — Matthew Gline, Chief Executive Officer · 2026-11-09 and "many hundreds" by early November, with hundreds of prescribers already writing. But pressed repeatedly on how $31 million squares with that patient count, he declined. The explanation offered is a stocking effect: revenue is booked when specialty pharmacies buy, and pharmacies bought ahead of demand. “there was a meaningful amount of undispensed drug that specialty pharmacies were holding as of 9/30. All of what they were holding at that point has now been dispensed” — Matthew Gline, Chief Executive Officer · 2026-11-09 — implying a tailwind to the September quarter and a modest headwind to December. That is a clean, plausible answer. It is also unfalsifiable until the next print. The genuinely new vocabulary here is paid drug and specialty pharmacy — logistics language that never appeared in Roivant's prior calls, because there was nothing to ship. Equally new: payer dynamics, which Gline described as "clean so far" with access ranging from a single prior-immunosuppressant requirement at large national plans to considerably tighter controls elsewhere. Any investor in this name is now underwriting reimbursement execution, not just clinical risk. That is a different company.A p-value nobody planned for
The louder event was unplanned. Roivant released Period 2 of the IMVT-1402 randomized-withdrawal study in difficult-to-treat RA because, simply, it worked. Roughly 92.5% of patients on 600 mg maintained an ACR20 response at week 28 versus about 75% on placebo; ACR50 separated at 80% versus 56%. The company's own thesis — deep IgG suppression — got its cleanest validation yet, because the 300 mg arm looked like placebo. That is a commercially valuable negative: it tells you the drug is not a commodity FcRn.That single sentence is the story of the quarter. On the August call, the stated plan was to deliver the data and the FDA path together.Those discussions are ongoing. Frankly, we had to disclose this data at this point because we hit a p-value unexpectedly.
The bow came untied. In August, Gline had also cautioned that “the results of that study may inform whether it is usable or not as one of our pivotal studies” — Matthew Gline, CEO · 2026-08-06 — the base case was that a randomized-withdrawal design might serve as one of two registrational trials. Now, with statistically significant data in hand, management believes a straight randomized controlled trial is the likelier Phase 3 shape: “I think it's relatively unlikely this will be a randomized withdrawal study” — Matthew Gline, Chief Executive Officer · 2026-11-09. The randomized withdrawal construct has flipped from an asset to a stepping stone.my dream, our dream for the second half of this year is that we can come back with everything tied as nicely into a bow as possible, which is to say the period 2 data, the FDA conversation...